Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943188 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01943188: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01943188 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01943188, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot phase I trial studies the side effects and best way to give stereotactic body radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer. Giving total body irradiation before a T-cell infusion stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. Chemotherapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the radiation therapy.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cyclophosphamide
- RADIATION stereotactic body radiation therapy
- BIOLOGICAL therapeutic autologous lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01943188
The ClinicalTrials.gov registry entry for NCT01943188 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01943188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01943188 about?
NCT01943188 is a clinical study titled "Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer". This pilot phase I trial studies the side effects and best way to give stereotactic body radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer. Giving total body irradiation before a T-cell infusion stops the growth of cancer cells by stopping them from dividing or...
What is the current status of trial NCT01943188?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-05.
What interventions are being tested in trial NCT01943188?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cyclophosphamide (DRUG), stereotactic body radiation therapy (RADIATION), therapeutic autologous lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01943188?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.